Literature DB >> 14738651

Is there a case for hepatitis C infection screening in the antenatal period?

Lucy Pembrey1, Marie-Louise Newell, Catherine Peckham.   

Abstract

Based on research evidence the UK National Screening Committee recently recommended that routine antenatal screening for hepatitis C virus (HCV) infection should not be introduced into the UK antenatal screening programme. In this paper we review the evidence on which this decision was based, addressing the criteria that need to be considered before the introduction of a new screening programme.

Entities:  

Mesh:

Year:  2003        PMID: 14738651     DOI: 10.1258/096914103771773230

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  5 in total

1.  Mother-to-child transmission of hepatitis C virus infection in Barcelona, Spain: a prospective study.

Authors:  Gemma Claret; Antoni Noguera; Cristina Esteva; Carmen Muñoz-Almagro; Emília Sánchez; Clàudia Fortuny
Journal:  Eur J Pediatr       Date:  2006-12-30       Impact factor: 3.183

Review 2.  Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease.

Authors:  Mahrukh Akbar Shaheen; Muhammad Idrees
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  Perinatal hepatitis C virus infection: diagnosis and management.

Authors:  S M Davison; G Mieli-Vergani; J Sira; D A Kelly
Journal:  Arch Dis Child       Date:  2006-09       Impact factor: 3.791

4.  CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020.

Authors:  Sarah Schillie; Carolyn Wester; Melissa Osborne; Laura Wesolowski; A Blythe Ryerson
Journal:  MMWR Recomm Rep       Date:  2020-04-10

5.  Prevalence and risk factors for Hepatitis C and HIV-1 infections among pregnant women in Central Brazil.

Authors:  Zelma B Costa; Gustavo C Machado; Mariza M Avelino; Clidenor Gomes Filho; Jose V Macedo Filho; Ana L Minuzzi; Marilia D Turchi; Mariane M A Stefani; Wayner Vieira de Souza; Celina Mt Martelli
Journal:  BMC Infect Dis       Date:  2009-07-27       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.